FDA Approves New Sugar Substitute Advantame

Insilico Medicine has reported that Rentosertib, an AI-discovered clinical candidate for idiopathic pulmonary fibrosis, demonstrates effectiveness in reversing the predicted biological age of IPF patients according to six independent proteomic aging clocks. The molecule's dual-purpose approach—targeting both a diagnosable disease and biological aging simultaneously—may open new pathways for anti-aging therapies...

The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.

InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.

The No Surprises Act's Independent Dispute Resolution process is undergoing a major technology transformation with a new centralized portal for open negotiations. This development introduces standardized procedures for billing disputes between healthcare providers and payers, but also raises critical questions about compliance, system capacity, and whether the portal adequately addresses persistent challenges in payment collection and claim eligibility determination.

Diagnosis coding practices in the Medicare Advantage (“MA”) risk adjustment space continue to be a top enforcement priority for the Department of Justice (“DOJ”).

Hospital and health system counsel face unprecedented challenges as AI transforms patient data into a critical asset, requiring navigation of complex de-identification strategies, state AI and privacy law compliance, and model ownership issues. This session provides in-house legal teams with a practical framework for managing AI-driven healthcare data transactions and governance structures they were never formally trained to handle.

Pharmacies frequently engage marketers, develop relationships with prescribers and offer services intended to attract and retain patients. While these efforts can support legitimate business growth, arrangements involving referral payments, copay waivers or free services may create significant regulatory and contractual exposure.

Organizations rushing to adopt AI often focus on eliminating all risks, inadvertently stalling beneficial implementations. This analysis explores how healthcare institutions can establish clear risk tolerance thresholds and implement multi-layered compliance frameworks that enable responsible AI adoption while maintaining appropriate safeguards and oversight mechanisms.

The US Department of Health and Human Services Office of Inspector General recently issued an unfavorable advisory opinion regarding physician consulting arrangements with compensation tied to product line sales, raising concerns about the medical device industry's approach to royalty payments.

How can multinational corporations effectively navigate the complex landscape of tax disputes across multiple European jurisdictions? This analysis examines strategic approaches and procedural considerations...

The SEC has proposed a comprehensive modernization of federal transfer agent rules that would expressly permit the use of blockchain technology as a master securityholder file. The proposal introduces technology-neutral language alongside new reporting requirements for distributed ledger technology usage and tokenized securities activity.

As federal climate disclosure rules face rescission and state-level mandates remain largely stalled, California's SB 253 greenhouse gas reporting requirement stands as the sole advancing framework, creating a fragmented compliance landscape where multistate companies must navigate divergent regulatory trajectories. With the SEC's 2024 climate rules stayed and proposed for elimination, and California's Air Resources Board finalizing implementation mechanics for November 2026 reporting deadlines, the operatio

The Ninth Circuit Court of Appeals vacated a preliminary injunction against Perplexity AI, determining that when an AI agent acts at a user's direction, it is the user—not the AI company—who "accesses" computer systems under federal and California computer fraud statutes. This landmark appellate decision addresses how existing computer-access laws apply to agentic artificial intelligence and has significant implications...

A federal court has struck down New York's Climate Change Superfund Act, which sought to recover $75 billion from fossil fuel companies based on historical emissions. The ruling found the Act preempted by the Clean Air Act, marking the first judicial decision on state climate superfund legislation and establishing that EPA's rescission of the endangerment finding does not alter preemption analysis.

The European Commission has adopted final Guidelines on exclusionary abuses of dominance under Article 102 TFEU, introducing a "workable effects approach" that narrows presumptions while expanding guidance on objective justifications and recognizing sustainability benefits as valid efficiencies for the first time. These Guidelines replace the 2008 Enforcement Priorities Guidance and are expected to significantly impact enforcement practices across EU Member States and beyond, particularly for digital market

In a recent PTAB decision, Director Squires addressed whether Microsoft's IPR petition should proceed despite Sandpiper CDN's discretionary denial request. The ruling hinged on two critical factors: the novelty of Microsoft's art citations and Sandpiper CDN's failure to disclose its own commonly assigned prior art during patent prosecution. This case provides important guidance on how patent owners' prosecution conduct can impact discretionary denial outcomes at the Patent Trial and Appeal Board.

The European Commission has proposed replacing the EU's three core procurement directives with a single, directly applicable Regulation that would fundamentally reshape how companies compete for public contracts across Member States. The reform introduces mandatory quality criteria thresholds, embeds ESG considerations as evaluation factors, and establishes new security and European-preference provisions that could restrict participation based on ownership, supply chain exposure, and strategic dependencies.

Early decisions about a start-up's legal structure can dramatically affect tax outcomes and financial returns as the company grows and reaches liquidity events. Understanding the Qualified Small Business Stock (QSBS) exemption and implementing proper structuring from the outset can significantly enhance returns for both founders and investors.

California's Air Resources Board has opened its voluntary reporting platform for the first cycle of greenhouse gas emissions disclosure under SB 253, establishing November 10, 2026 as the deadline and clarifying that companies may submit existing reports rather than creating new CARB-specific documents. The guidance addresses critical implementation questions including consolidated reporting mechanics, fee assessment structures, and first-year enforcement discretion for entities without established data col